Figure 5. SpeC-based TTS therapy of established HT-29 colon cancer.

A) Schematic illustration of the xenograft solid tumor model experimental timeline. NSG mice with established (3 week) intraperitoneal human HT-29 tumors were injected once with human PBMC intraperitoneally, followed by 8 daily intravenous injections of scFv5T4::SpeC_D203A, or individual controls (2 µM/kg/injection). B) Primary tumor size was evaluated throughout the experimental timeline by external caliper measurements. Twenty-eight days post-final injection, final tumor volume was measured (panel C) and metastatic score (panel D) evaluated. All groups contained n = 4, with exception of saline alone control (n = 3). *p<0.05, **p<0.005. Gross pathology and metastases in representative NSG mice with HT-29 tumors treated with scFv5T4::SpeC_Y15A/D203A or scFv5T4::SpeC_D203A. The primary tumor is labeled with a triangle and metastases are labeled with arrows.